Oops! It appears that you have disabled your Javascript. In order for you to see this page as it is meant to appear, we ask that you please re-enable your Javascript!

HOWARU® Balance

HOWARU Products, athletic woman climb satires to excise

HOWARU® Balance

HOWARU® Balance

Containing 2 of the most studied probiotic strains for gut and immune health, Lactobacillus acidophilus NCFM® and Bifidobacterium lactis HN019™, HOWARU® Balance helps deliver healthy digestion and natural immunity in 1 convenient supplement.

Digestive Health

In a 2 week, triple-blind, placebo-controlled trial, 100 healthy volunteers were randomized into 3 groups during 14 days of treatment with a wash-out period of 7 days: Group 1 – probiotics of high dose (1.72X1010 CFU per day), Group 2 – probiotics of lose dose (1.8X109 CFU per day), or Group 3 – placebo. The study was to assess the impact of Bifidobacterium lactis HN019™ on colonic transit times at different dose.

Data showed that high-dose group reduced colonic transit time by 28 hours, compared to 18 hours for the low-dose group and no substantial improvement in the placebo group. In the meantime, Bifidobacterium lactis HN019™ at high or low doses significantly modulated gut microflora, resulting in positive digestive comfort. 

Bar Chart of B.lactis HN019, Howaru Balance

Multiple human intervention trials have shown that L. acidophilus NCFM® and B. lactis HN019™ can positively modulate gut microflora, resulting in enhanced levels of beneficial bacteria. Collectively, these findings support the health-enhancing attributes associated with L. acidophilus NCFM® and B. lactis HN019™ consumption and strongly position these strains as premium digestive health probiotics.

Immunity Health

The pre-post intervention trial was conducted to determine dose-effect relation of dietary supplementation with probiotic lactic acid bacteria (LAB) on peripheral blood NK cell activity in healthy elderly subjects. Twenty-seven volunteers consumed low-fat/low-lactose milk supplemented with known immunostimulatory LAB strains (Lactobacillus rhamnosus HN001™ or Bifidobacterium lactis HN019™) for a period of 3 weeks. A dietary run-in of milk alone was shown to have no significant effect on NK cells. In contrast, the proportion of CD56-positive lymphocytes in peripheral circulation was higher following consumption of either LAB strain, and ex vivo PBMC tumoricidal activity against K562 cells was also increased. Supplementation with HN001™ or HN019™ increased tumoricidal activity by an average of 101 and 62%, respectively; these increases were significantly correlated with age, with subjects older than 70 experiencing significantly greater improvements than those under 70. These results demonstrate that dietary consumption of Lactobacillus rhamnosus HN001™ and Bifidobacterium lactis HN019™ in a milk-based diet may offer benefits to elderly consumers to combat some of the deleterious effects of immunosenescence on cellular immunity.

Table Chart of HOWARU Balance B.Lactis HN019


Waller PA, et al. 2011. Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults. Scand J Gastroenterol. 9: 1057-1064.
Dietary probiotic supplementation enhances natural killer cell activity in the elderly: an investigation of age-related immunological changes. J Clin Immunol. 2001, 21:264-271.